Table 1 Summary data for studies comparing outcomes between biopsy and prostatectomy included for this review
Author (year ) | Study characteristic a | Patient characteristic | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study region (interval) | Study size, n | No. Gleason score change, n (%) | No. Upstaging, n (%) | Definition of Gleason score change (from bGS to pGS) | Definition of upstaging | Mean age, years | Mean PSA, ng/mL | Mean PV, mL | bGS | Clinical T-stage | No. cores obtained, n | |
Audenet 2017 [14] | France (2006–2013) | 1791 | 1093(61.0) | – | ≤ 6 to ≥ 7 | – | NA | NA | NA | ≤ 6 | T1c–3b | 10–14 |
Bullock 2019 [15] | UK (2011–2016) | 17598 | 4489(25.5) | – | Any upgrading | – | 63.2 | 10.06 | NA | > 7: 14% | T1–4 | NR |
Dinh 2015 [16] | USA (2010–2011) | 10288 | 4467(43.4) | 992(9.6) | ≤ 6 to ≥ 7 | cT1–2N0 to pT3a–4N0–1 | 59.5 | 5.2 | NA | ≤ 6 | T1c–2a | 12 |
Dinizo 2018 [6] | USA (2003–2014) | 2256 | 784(34.8) | 163(7.2) | ≤ 6 to ≥ 7 | cT1–2 to pT3a–4 | NA | NA | NA | ≤ 6 | T1–2a | ≥ 12 |
Epstein 2012 [17] | USA (2002–2010) | 5071 | 1841(36.3) | – | ≤ 6 to ≥ 7 | – | NA | NA | NA | ≤ 6 | T1–2a | NR |
Ferro 2019 [18] | Italy (2006–2013) | 260 | 166(63.8) | – | ≤ 6 to ≥ 7 | – | 62.2 | 5.8 | 51.9 | > 3 + 4: 13% | T1c–2a | Median 10, Range 6–40 |
Gondo 2015 [9] | USA (2005–2013) | 1317 | 115(8.7) | – | 3 + 4 to ≤ 6 | – | NA | NA | NA | 3 + 4 | T1c–4 | ≥ 12 |
Jalloh 2015 [19] | USA (1990–2012) | 4231 | 1123(26.5) | 499(11.8) | ≤ 6 to ≥ 7 | cT1–2N0 to pT3a–4N0–1 | 59.9 | NA | NA | ≤ 6 | T1–2 | Mean 9.15 |
Jeon 2017 [10] | USA and Korea (2006–2015) | 854 | 484(56.7) | 88(10.3) | ≤ 6 to ≥ 7 | cT1–2 to pT3a–4 | NA | NA | NA | ≤ 6 | T1c–2a | NR |
Leeman 2019 [11] | Germany (1992–2017) | 3571 | 115(3.2) | 245(6.9) | ≤ 6 to ≥ 7 | cT1–2 to pT3a–4 | NA | NA | NA | ≤ 6 | T1c–2 | Median 9 |
Luzzago 2018 [20] | Italy (2012–2016) | 383 | 134(35.0) | bGS≤ 6, cT1–2N0 to pGS ≥ 7 and/or pT3a–4N0–1 | NA | NA | NA | ≤ 6 | T1c–2a | ≥ 12 | ||
Lyon 2016 [21] | USA (1999–2015) | 1256 | 647(51.5) | – | ≤ 6 to ≥ 7 | – | NA | NA | NA | ≤ 6 | T1–4 | ≥ 6 |
Kim 2013 [22] | Korea (2005–2011) | 451 | 194(43.0) | – | ≤ 6 to ≥ 7 | – | 64 | 8.79 | 38.1 | ≤ 6 | T1–2 | Mean 11.5, Range 2–27 |
Kwon 2016 [23] | USA (2006–2015) | 217 | 58(26.7) | – | ≤ 6 to ≥ 7 | – | NA | NA | NA | ≤ 6 | T1–2a | NR |
Magheli 2010 [24] | Germany (1999–2004) | 610 | 308(50.5) | – | ≤ 6 to ≥ 7 | – | NA | NA | NA | ≤ 6 | T1–2 | NR |
Martin 2017 [25] | USA (2005–2008) | 136 | 19(14.0) | – | ≤ 7 to ≥ 8 | – | NA | NA | NA | ≤ 7 | T1c–2 | ≥ 10 |
Mizuno 2016 [26] | Japan (2005–2011) | 284 | 154 (54.2) | bGS ≤ 6, cT1–2 to pGS ≥ 7 and/or pT3a–4 | NA | NA | NA | ≤ 6 | T1c–2a | NR | ||
Morlacco 2016 [5] | USA (2006–2014) | 1190 | 156(13.1) | 205(17.2) | 3 + 4 to ≥ 4 + 3 | cT1–2 to pT3a–4 | NA | NA | NA | 3 + 4 | T1c–2a | Median 12, IQR 12–14 |
201(16.9) | 3 + 4 to ≤ 6 | |||||||||||
295 (24.8) | bGS = 3 + 4, cT1–2N0 to pGS ≥ 4 + 3 and/or pT3a–4N0–1 | |||||||||||
Oh 2012 [27] | Korea (2003–2010) | 505 | 253(50.1) | – | ≤ 6 to ≥ 7 | – | 65.2 | 7.79 | 39.5 | ≤ 6 | T1c–2a | ≥ 12 |
Pietzak 2014 [28] | USA (1998–2008) | 400 | - | 49(12.3) | – | cT1-2 to pT3a-4 | NA | NA | NA | ≤ 6 | T1c–2a | ≥ 10 |
Shoag 2020 [29] | USA (2010–2015) | 11025 | 2255(45.2) | – | Any downgrading | – | NA | NA | NA | 6–10 | T1–3 | NR |
Weiner 2015 [30] | USA (2010–2011) | 17943 | 8113(45.2) | bGS ≤ 6, cT1-2N0 to pGS ≥ 7 and/or pT3a–4N0–1 | NA | NA | NA | ≤ 6 | T1–2a | NR | ||
Wong 2012 [31] | Canada, Australia and UK (2003–2010) | 644 | 333 | bGS ≤ 6, cT1–2 to pGS ≥ 8 and/or pT3a–4 | NA | NA | NA | ≤ 6 | T1–2a | 8–12 | ||
Zanaty 2018 [12] | Canada (2006–2014) | 237 | 134(56.5) | – | ≤ 6 to ≥ 7 | – | 58.6 | 38.4 | 5.03 | NR | T1c–2a | NR |